Use of post-transplant Cyclophosphamide (PTCy) for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) has reduced the incidence of graft versus host disease (GvHD), and expanded donor options for patients to include haploidentical and mismatched unrelated donors. Though PTCy is effective at reducing acute GvHD, 30-40% of patients receiving peripheral blood stem cell (PBSC) grafts are at risk of chronic GvHD, which creates significant long-term consequences. There are several other risks associated with PTCy, including a higher rate of serious infections, organ dysfunction and delayed immune reconstitution.